Why Is Biohaven Stock Falling On Thursday?

Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations. Latest Ratings for BHVN Date Firm Action From To Mar 2022 Mizuho Maintains Buy Jan 2022 Morgan Stanley Maintains Equal-Weight Nov 2021 Mizuho Maintains Buy View More Analyst Ratings for BHVN View the Latest Analyst Ratings…

Read More